Fatima Karzai, MD, on Prostate Cancer: Treatment Study Results

2018 Genitourinary Cancers Symposium
Tweet this page

Fatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected population (Abstract 163).

Advertisement

Advertisement



Advertisement